Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Aprameya Engineering Ltd
| H2 & FY25 Earnings Conference Call
Summary : Aprameya Engineering, a turnkey healthcare solutions provider, reported strong FY25 growth driven by proprietary products and government projects, while actively managing high debtor days and expanding geographically.
Management Perspective positive : Management expressed immense pleasure in their maiden earnings call. They highlighted significant growth, improved margins, and a healthy order book. They conveyed confidence in their ability to create long-term value and drive sustained growth through innovation and operational efficiencies.
Concall Report Analysis & Insights
Business Overview
- Evolved from medical equipment distributor to comprehensive turnkey healthcare solution provider.
- Delivers end-to-end services for critical care units, modular OTs, and prefabricated structures.
- Operations include healthcare infrastructure projects (90% revenue), medical equipment solutions (8%), and services/CAMCs (2%).
- Installed over 2,000 critical care beds and 180+ dialysis centers since 2020.
- Serves as a one-stop partner for infrastructure, equipment, and maintenance services.
Future Growth Prospects
- Expanding geographic footprint to underdeveloped states like Bihar, Assam, and Sikkim.
- Introducing proprietary solutions for super specialty hospitals, including EP lab systems and mobile CT scans.
- Developing mobile stroke units with in-built CT scans for critical golden hour treatment.
- Planning entry into robotic surgery platforms with unique remote operation capabilities.
- Healthy INR60 crore order book executable within five to six months, with aspirations for faster growth than industry CAGR.
Management Insights
- Revenue grew 108% year-on-year to INR136 crores in FY'25, driven by high-margin turnkey projects.
- EBITDA increased 267% year-on-year to INR 25 crores, with margins improving to 18%.
- PAT rose 364% year-on-year to INR 16 crores, with margins improving to 12%.
- Focusing on good margin products and selective tenders after evaluating costing and margins.
- Committed to maintaining current EBITDA levels and improving operational efficiencies.
Signs of Skepticism
- High debtor days (INR120 crores) relative to total revenue (INR136 crores) raises working capital concerns.
- Negative cash flow from operations for three consecutive years suggests ongoing liquidity challenges.
- Management avoided providing specific quantitative guidance for future order book growth or capex figures for expansion.
- Reliance on government tenders, which inherently carry risks of delayed payments and stringent terms.
Risk Factors
- Negative cash flow from operations observed in the last three financial years.
- High debtor days, particularly from government projects, impacting working capital management.
- Dependence on government tenders and their payment cycles, which can be extended.
- Potential for liquidity damages or debatable issues in government contracts, though not classified as bad debt.
Good To Know
- Company got listed on the NSE Emerge in August 2024.
- Raised INR29.2 crores through IPO in August 2024 to strengthen working capital and support expansion.
- India's healthcare system faces a major infrastructure gap, with government allocating INR98,000 crores in FY'25.
- Medical equipment industry projected to grow from $11 billion (2022) to $50 billion by 2030.
- MSME 45-day payment rule is not applicable to government contracts or companies above INR100 crores revenue.
Key Drivers
- Government healthcare infrastructure investment.
- Proprietary medical technology solutions.
- Geographic expansion into new states.
- Growing order book execution.
Key Analyst Discussions
Competitive Environment
- No listed competitors in the turnkey healthcare infrastructure space.
- Regional unlisted players lack the experience and horizontal bandwidth for large government tenders.
- Multinational companies typically focus on equipment supply, not end-to-end turnkey projects.
- Aprameya's strong entry barriers and proprietary products give it a competitive edge.
Market Trends & Consumer Behavior
- Government policy aims for one medical college per district, driving infrastructure demand.
- Underdeveloped states like Bihar and Assam have allocated funds but lack project execution.
- Ayushman Bharat scheme is increasing earnings for trust and private hospitals, leading to new opportunities.
- Hospitals are willing to invest in lifesaving, proprietary solutions that address long-standing problems.
Financial Highlights
- Debtor cycle reduced from 8 months to 6 months, aiming for 4-5 months to improve cash flow.
- FY25 revenue (INR136 crores) is from traditional business, unlike FY22 (INR200 crores) which included one-time COVID orders.
- Trade payable cycle is around 2-3 months, significantly shorter than receivable cycle.
- Service model offers good margins, with fixed CMC contracts post-warranty (4-6% of project value, 5-10% annual escalation).
Product Composition
- Turnkey business accounts for 85-90% of revenue, with 70-75% of that being proprietary products.
- Trading business contributes 7-8% of revenue, with services and CAMCs making up the remainder.
- Service segment is expected to grow as more projects transition into the post-warranty phase.
- Proprietary products like EP labs, mobile CTs, and stroke units are key drivers of higher margins.
Strategic Considerations
- Geographic expansion into new states is focused on underdeveloped regions with available government funds.
- Capex for new state entry is a gradual process, focusing on brownfield projects to manage cash flow.
- Private sector engagement is selective, targeting projects with good margins and patient flow, avoiding low-margin contracts.
- New OEM partnerships with multinational companies are in pipeline, but not yet finalized.